Their research aims to produce toxic enzymes as inactive pro-enzymes in bacteria, which can be activated through simple pH and/or temperature shifts. This technology addresses the challenges of producing large quantities of active enzymes for industrial synthetic applications or pharmacologic replacement therapies. The company's initial focus is on using the catalytic core of the human transglutaminase 1 enzyme to prove the concept, with potential applications in treating lamellar icthyosis and developing novel biomaterials for various industries. APC Biotechnology Services is also seeking clients for custom peptide synthesis and strategic partners and licensees for its technology.